Conatus Pharma (NASDAQ:CNAT) Price Target & New Coverage by Roth Capital
Roth Capital analyst started coverage on Conatus Pharma (NASDAQ:CNAT) with a $20.0 target and Buy rating. The target indicates a potential upside of 335.73 % from company’s last stock price.
The initiation is well-received by investors, as NASDAQ:CNAT is at the moment trading 2.43% higher at $4.21 as of 4:08 PM New York time. Conatus Pharma’s stock is 0% over the last 200 days. It has underperformed the Standard & Poor’s 500 index, which has surged 6.00% over the same time period.
Mpm Asset Management Llc had the largest stake with ownership of 1.19M shares as of Q2 2015 for 0.78% of the long stock exposure. Courage Capital Management Llc is another notably bullish investment manager who is possessing 100,000 shares of Conatus Pharma or 0.08% of their long stock exposure. Moreover, Axa have 0.01% of their long stock exposure invested in the company for 1.09M shares. The United Kingdom-based fund Polar Capital Llp revealed it had purchased a stake worth about 0.01% of the investment manager’s stock portfolio in Conatus Pharma. The California-based fund Reilly Financial Advisors Llc is also positive about the stock, possessing 156,531 shares or 0.01% of their long stock exposure.
Conatus Pharma (NASDAQ:CNAT) Profile
Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment.
Conatus Pharma (NASDAQ:CNAT) traded up 2.43% on 8 February, hitting $4.21. A total of 197,255 shares of the company’s stock traded hands. This is down from average of 343,911 shares. Conatus Pharma has a 52 week low of $1.73 and a 52 week high of $9.4. The company has a market cap of $126.32M and a P/E ratio of 0.
Get the latest Conatus Pharma (NASDAQ:CNAT) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post Conatus Pharma (NASDAQ:CNAT) Is Now Covered by Roth Capital. They Set a Buy Rating on the Stock and $20.0 Price Target appeared first on Octafinance.